Female Reproductive Physiology

Hypothalamic-Pituitary-Ovarian (HPO) Axis Control

• GnRH (gonadotropin-releasing hormone) is released from the hypothalamus in a pulsatile pattern (every 60–90 minutes); this pulsatile secretion is critical for normal FSH and LH stimulation
• Continuous GnRH exposure paradoxically suppresses gonadotropin release (used clinically in GnRH agonists)
• Anterior pituitary responds to GnRH by releasing FSH and LH in a coordinated fashion

Follicular Phase (Days 1–14 of 28-day cycle)

• FSH stimulates granulosa cell proliferation and estrogen production from developing primary and secondary follicles
• Rising estrogen provides negative feedback to the pituitary, suppressing FSH and LH levels (maintains follicular dominance of one primary follicle)
• Aromatase converts androgens (produced by thecal cells) to estrogen in granulosa cells (two-cell, two-gonadotropin theory)
• Estrogen acts on endometrium to promote proliferation and increased endometrial thickness

Ovulation (LH Surge, ~Day 14)

• Positive feedback from high estrogen levels (threshold >200 pg/mL for 24–48 hours) triggers the LH surge
• LH surge causes ovulation within 24–36 hours via increased intrafollicular pressure, prostaglandin release, and enzyme activation
• The dominant follicle (usually 18–25 mm) ruptures; oocyte completes meiosis I and arrests in metaphase II

Luteal Phase (Days 15–28)

• Corpus luteum (remnant of ovulated follicle) secretes progesterone and inhibin
• Progesterone causes negative feedback on GnRH, FSH, and LH (maintains luteal phase by preventing new follicle recruitment)
• Progesterone acts on endometrium to promote secretory transformation, glandular development, and preparation for implantation
• If fertilization does not occur, corpus luteum regresses after ~14 days (luteolysis); progesterone and estrogen decline, triggering menstruation
• If fertilization occurs, human chorionic gonadotropin (hCG) from the trophoblast sustains the corpus luteum

Menstruation

• Decline in progesterone and estrogen (after corpus luteum regression) triggers endometrial shedding
• Increased prostaglandins (PGE2, PGF2α) promote uterine contractions and vasoconstriction
• Normal menstrual blood loss is <80 mL over 3–7 days; passage of tissue, clots, and blood

Endometrial Changes

• Proliferative phase (follicular): estrogen-driven thickening to 8–12 mm; increased vascularity and glandular activity
• Secretory phase (luteal): progesterone-driven maturation; coiled glands, stromal edema, increased vascularity
• Menstrual phase: ischemia and necrosis of functional layer; shedding of endometrium

Normal Menstrual Cycle Patterns

• Menarche typically occurs at ages 12–13 years; cycles may be irregular for the first 1–2 years
• Regular cycle length: 21–35 days (average 28 days)
• Menstrual flow duration: 3–7 days with total blood loss <80 mL
• Menstrual products may include clots and tissue fragments (normal if not excessive)

Ovulatory Cycle Signs (Subtle but Important)

• Mittelschmerz: unilateral pelvic/lower abdominal pain at ovulation (due to ovarian capsule distension and peritoneal irritation)
• Changes in cervical mucus: at ovulation, cervical mucus becomes clear, stretchy, and abundant (ferning pattern due to high estrogen); "spinnbarkeit" (elasticity) indicates fertility window
• Basal body temperature (BBT) shift: slight rise (~0.5°C) in basal temperature after ovulation (progesterone-induced); used retrospectively to confirm ovulation
• Breast tenderness and mood changes in luteal phase (progesterone-related)

Premenstrual Symptoms

• Premenstrual syndrome (PMS): mood changes, bloating, breast tenderness, fatigue in luteal phase; resolves with menstruation
• Premenstrual dysphoric disorder (PMDD): severe mood symptoms (depression, anxiety, irritability) affecting daily function; 3–8% of menstruating individuals

Hormonal Fluctuations and Symptoms

• Estrogen dominance (follicular phase): may promote endometrial proliferation, mood elevation
• Progesterone dominance (luteal phase): promotes secretion, thermogenesis, increased appetite; may cause bloating and mood changes
• Low hormone phases (early menstrual phase): may trigger migraines in hormonally sensitive individuals

Hormonal Assessment (Serum Levels)

• Day 3 FSH and estradiol (E2): measure on cycle day 2–4 to assess ovarian reserve; elevated FSH (>10 mIU/mL) or high E2 suggests diminished reserve
• Midcycle LH and estradiol: high estradiol (>200 pg/mL) triggers LH surge; can confirm ovulatory cycle
• Luteal phase progesterone (day 21 of 28-day cycle, or 7 days before next menses): >3 ng/mL suggests ovulation; >15 ng/mL indicates adequate luteal function
• Prolactin, TSH, testosterone: screen if amenorrhea or irregular cycles present

Ovulation Confirmation Methods

• Serum progesterone: gold standard; >3 ng/mL confirms ovulation occurred
• Ovulation predictor kits (OPKs): detect urinary LH surge 24–36 hours before ovulation; useful for fertility monitoring
• Transvaginal ultrasound: visualize follicular development through follicular phase; confirms ovulation by documenting follicle disappearance and free fluid in pelvis
• Basal body temperature charting: shows biphasic pattern (low then elevated) confirming retrospective ovulation but less reliable than progesterone

Endometrial Assessment

• Transvaginal ultrasound: measure endometrial thickness in proliferative phase (should be 8–12 mm for optimal receptivity); assess endometrial texture and vascularity
• Endometrial biopsy: historically used to assess secretory changes but now rarely done for routine diagnosis; reserved for abnormal bleeding or recurrent pregnancy loss evaluation

Menstrual Cycle Documentation

• Menstrual calendar/diary: track cycle length, flow duration, symptoms; defines regularity and identifies patterns
• Cycle length variability: normal if ≤7 days; >7-day variation suggests anovulation or other dysfunction

Supportive and Lifestyle Measures

• Regular exercise and balanced nutrition: maintain healthy BMI (18.5–24.9); obesity and extreme leanness both disrupt HPO axis
• Stress reduction: chronic stress elevates cortisol, suppressing GnRH and disrupting cycles
• Sleep optimization: inadequate sleep disrupts circadian regulation of reproductive hormones
• Cycle tracking: helps patients understand their

The facts stems hinge on

• Luteal phase length is fixed (~14 days): cycle-length variation comes almost entirely from the follicular phase. A woman with 35-day cycles ovulates around day 21, not day 14 — the single most common timing trap in fertility and dating questions.
• Estrogen feedback flips: low-to-moderate estradiol exerts negative feedback, but sustained high estradiol (roughly two days above the mid-cycle threshold) switches to positive feedback, producing the LH surge. Progesterone does not trigger the surge; it restores negative feedback afterward.
• Two-cell, two-gonadotropin: LH drives theca cells to make androstenedione; FSH induces aromatase in granulosa cells to convert it to estradiol. Aromatase deficiency or absent theca androgen supply therefore yields low estrogen with high gonadotropins.
• Meiotic arrest: the primary oocyte is arrested in prophase I from fetal life until the LH surge completes meiosis I; the secondary oocyte then arrests in metaphase II and only completes meiosis II if fertilized.
• Best next step to confirm ovulation: a mid-luteal serum progesterone (about 7 days before expected menses), the approach endorsed by ASRM/ACOG infertility evaluation guidance. Basal body temperature charting is retrospective and less reliable; do not choose it as the confirmatory test.

Associations and distractors

• Pulsatile vs continuous GnRH: pulsatile GnRH stimulates gonadotropins (fertility induction); continuous GnRH agonist exposure (leuprolide) downregulates receptors and suppresses the axis — used for endometriosis, fibroids, and central precocious puberty.
• Inhibin B selectively suppresses FSH (granulosa-derived); rising FSH with falling inhibin is the earliest hormonal marker of declining ovarian reserve and of the menopausal transition. Menopause itself is a clinical diagnosis (12 months of amenorrhea) per ACOG — routine FSH testing is not required.
• Progesterone is thermogenic and makes cervical mucus thick and scant; estrogen makes it clear and stretchy (spinnbarkeit, ferning). This is the mechanism behind progestin-only contraception.
• hCG rescues the corpus luteum via the LH receptor; the luteal–placental shift means the placenta assumes progesterone production during the late first trimester, so early luteectomy causes pregnancy loss but later removal does not.
• ACOG frames the menstrual cycle as a vital sign in adolescents — persistent irregularity beyond the first few post-menarchal years warrants evaluation, not reassurance.